BR112016002342A8 - microesfera entecavir, método para preparação de uma microesfera entecavir, e, composição farmacêutica - Google Patents

microesfera entecavir, método para preparação de uma microesfera entecavir, e, composição farmacêutica

Info

Publication number
BR112016002342A8
BR112016002342A8 BR112016002342A BR112016002342A BR112016002342A8 BR 112016002342 A8 BR112016002342 A8 BR 112016002342A8 BR 112016002342 A BR112016002342 A BR 112016002342A BR 112016002342 A BR112016002342 A BR 112016002342A BR 112016002342 A8 BR112016002342 A8 BR 112016002342A8
Authority
BR
Brazil
Prior art keywords
entecavir
microspheres
microsphere
pharmaceutical composition
solvent
Prior art date
Application number
BR112016002342A
Other languages
English (en)
Other versions
BR112016002342A2 (pt
Inventor
Keun Lee Deok
Hoi Cha Kyung
Eom Shin
Original Assignee
Dong Kook Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong Kook Pharm Co Ltd filed Critical Dong Kook Pharm Co Ltd
Publication of BR112016002342A2 publication Critical patent/BR112016002342A2/pt
Publication of BR112016002342A8 publication Critical patent/BR112016002342A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1 / 1 resumo “microesfera entecavir, e, composiã‡ãƒo fa rma c㚠u t ica ” a presente invenã§ã£o se refere a microesferas entecavir e uma composiã§ã£o farmacãªutica para administraã§ã£o parental contendo a mesma. as microesferas entecavir sã£o fabricadas por um mã©todo compreendendo as etapas de: dissolver entecavir e um polã­mero biocompatã­vel biodegradã¡vel em pelo menos um solvente; colocar a soluã§ã£o de entecavir e polã­mero biocompatã­vel biodegradã¡vel em uma soluã§ã£o de polã­mero hidrofã­lico, seguida de agitaã§ã£o, para formar microesferas; e remover o solvente. a entecavir ã© suficientemente vedada na microesfera entecavir em aproximadamente 80% ou mais com base na quantidade de entrada, e a eluiã§ã£o da entecavir ã© mantida por 30 dias ou mais, e entã£o as microesferas entecavir podem continuamente exibir eficã¡cia, assim, melhorando a observã¢ncia da medicaã§ã£o dos pacientes.
BR112016002342A 2013-08-06 2013-08-06 microesfera entecavir, método para preparação de uma microesfera entecavir, e, composição farmacêutica BR112016002342A8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2013/007085 WO2015020240A1 (ko) 2013-08-06 2013-08-06 엔테카비어 미립구 및 이를 포함하는 비경구투여용 약제학적 조성물

Publications (2)

Publication Number Publication Date
BR112016002342A2 BR112016002342A2 (pt) 2017-08-29
BR112016002342A8 true BR112016002342A8 (pt) 2018-01-23

Family

ID=52461556

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016002342A BR112016002342A8 (pt) 2013-08-06 2013-08-06 microesfera entecavir, método para preparação de uma microesfera entecavir, e, composição farmacêutica

Country Status (8)

Country Link
US (1) US20160175313A1 (pt)
EP (1) EP3031449A4 (pt)
JP (1) JP2016527308A (pt)
CN (1) CN105722503A (pt)
BR (1) BR112016002342A8 (pt)
MX (1) MX2016001607A (pt)
RU (1) RU2016107827A (pt)
WO (1) WO2015020240A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3365020T3 (pl) * 2015-10-22 2020-03-31 Delsitech Oy Preparat depot kompozytu hydrożelowego
KR102047983B1 (ko) * 2017-11-30 2019-11-22 주식회사 지투지바이오 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법
CN110483756B (zh) * 2018-03-01 2021-04-27 苏州大学 末端含硫辛酰基的星型聚合物的制备方法及聚合物纳米粒子的制备方法
CN108938572B (zh) * 2018-09-27 2021-04-20 烟台大学 一种含有恩替卡韦的长效注射微球及其制备方法
CN113081952A (zh) * 2021-04-12 2021-07-09 山东谷雨春生物科技有限公司 一种含有恩替卡韦的长效注射凝胶
KR20230036886A (ko) * 2021-09-08 2023-03-15 주식회사 아울바이오 생분해성 고분자를 이용한 서방형 미립구 및 이의 제조방법
CN116650497A (zh) * 2022-09-30 2023-08-29 广州帝奇医药技术有限公司 一种抗病毒药物组合物及其制备工艺与应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366734A (en) 1981-02-16 1994-11-22 Zeneca Limited Continuous release pharmaceutical compositions
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
CH660302A5 (fr) 1984-10-17 1987-04-15 Debiopharm Sa Procede de micro-encapsulation en phase heterogene de substances medicamenteuses hydrosolubles.
NZ276088A (en) 1993-11-19 1999-07-29 Janssen Pharmaceutica Nv [(1,2-benzisoxazol-3-yl)-1-piperidinyl-alkyl-6,7,8,9-tetrahydro-4h- pyrido[1,2-a]-pyrimidin-4-one derivatives (ie risperidone)
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
AU752552C (en) 1997-09-30 2003-09-11 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
AU3108299A (en) * 1998-03-18 1999-10-11 University Technology Corporation Sustained-release composition including amorphous polymer
KR100321854B1 (ko) * 1998-12-30 2002-08-28 동국제약 주식회사 루테이나이징 호르몬 릴리싱 호르몬 동족체를 함유하는 장기 서방출성 미립구 및 그의 제조방법
US6306425B1 (en) 1999-04-09 2001-10-23 Southern Research Institute Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
WO2003055470A1 (fr) 2001-12-26 2003-07-10 Takeda Chemical Industries, Ltd. Nouvelle microsphere et son procede de production
TWI275392B (en) * 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
KR100566573B1 (ko) 2002-04-13 2006-03-31 주식회사 펩트론 Ｌｈｒｈ 동족체를 함유하는 서방성 미립구의 제조방법
KR100816065B1 (ko) * 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
US20110206773A1 (en) * 2008-05-20 2011-08-25 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
KR100963435B1 (ko) * 2008-06-19 2010-06-17 한국과학기술연구원 서방형 약물전달 및 조직재생용 덮인 다공성 생분해성고분자 미립구의 제조 방법
KR101113044B1 (ko) * 2008-08-29 2012-02-27 동국제약 주식회사 용매교류증발법에 의한 서방출성 미립구의 제조방법
KR20110026311A (ko) * 2009-09-07 2011-03-15 제일약품주식회사 엔테카비어의 신규한 염
CN102058521A (zh) * 2009-11-17 2011-05-18 天津天成制药有限公司 一种含活性成分恩替卡韦经注射给药的制剂
KR101594820B1 (ko) * 2011-06-16 2016-02-17 건일제약 주식회사 엔테카비르를 함유하는 미립구 및 이의 제조방법
JP2013053103A (ja) * 2011-09-05 2013-03-21 Ltt Bio-Pharma Co Ltd 薬物を封入した肝臓集積性ナノ粒子
CN102908312B (zh) * 2011-11-10 2014-06-04 陈小花 抗乙肝病毒液体组合物
TWI568453B (zh) * 2011-11-22 2017-02-01 原創生醫股份有限公司 具有螯合型複合微胞之藥物載體及其應用
KR101285008B1 (ko) * 2012-04-18 2013-07-10 제일약품주식회사 저용량 엔테카비어의 경구투여 제제의 제조방법

Also Published As

Publication number Publication date
CN105722503A (zh) 2016-06-29
EP3031449A4 (en) 2017-05-10
MX2016001607A (es) 2016-06-06
JP2016527308A (ja) 2016-09-08
BR112016002342A2 (pt) 2017-08-29
US20160175313A1 (en) 2016-06-23
RU2016107827A (ru) 2017-09-14
WO2015020240A1 (ko) 2015-02-12
EP3031449A1 (en) 2016-06-15

Similar Documents

Publication Publication Date Title
BR112016002342A8 (pt) microesfera entecavir, método para preparação de uma microesfera entecavir, e, composição farmacêutica
BR112015025172A2 (pt) composição farmacêutica
MX2020012041A (es) Formulacion farmaceutica.
BR112014028600A8 (pt) Formulações de suspensão compreendendo anticorpo monoclonal de alta concentração, seu método de preparação, seu uso e dispositivo para sua administração subcutânea, e método para produção de um artigo de fabricação
BR112012024379A2 (pt) "peptídeos glucagon, seu uso, bem como composição farmacêutica"
MX2019007119A (es) Preparado oral del activador de glucocinasa y preparacion del mismo.
BR112015008186A2 (pt) formulação de um anticorpo estável e de baixa viscosidade
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
BR112023024646A2 (pt) Composto tetacíclico fundido, método de preparação do mesmo e aplicação do mesmo na medicina
BR112012000287B8 (pt) composição farmacêutica para um inibidor de protease viral de hepatite c
AR125407A2 (es) Procedimiento para la preparación de partículas de polímero farmacéuticas y/o cosméticas, y procedimiento para la preparación de composiciones farmacéuticas y/o cosméticas que comprenden dichas partículas
BR112015013695A2 (pt) composição farmacêutica, e, métodos para tratamento e para prevenção de uma infecção por hiv
RU2012103538A (ru) Композиции и способы ингибирования пути jak
EA201490544A1 (ru) Препараты и лекарственные формы на основе окисленных фосфолипидов
BR112015017246A8 (pt) composição farmacêutica aquosa, seu uso e seringa
EA201691490A1 (ru) Фармацевтическая композиция, содержащая бринзоламид
BR112019002635A2 (pt) formulação farmacêutica para administração oral, método de preparo da formulação farmacêutica para administração oral e formulação compósita em cápsula dura que contém cloridrato de tansulosina
BR112014017141A2 (pt) método de tratamento de diabetes usando-se apolipoproteína a-iv não glicosilada
EA201690005A1 (ru) Состав с модифицированной кинетикой высвобождения
AR059927A1 (es) Metodos para la estabilizacion de composiciones inestables a la oxidacion y composiciones oftalmicas estabilizadas
BR112017022755A2 (pt) formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual
BR112013030391A2 (pt) derivados de piperidina 3- espirocíclicos como agonistas dos receptores de grelina
BR112015007360A2 (pt) composição farmacêutica, e, método para a preparação de uma droga de combinação
BR112013019876A2 (pt) formulação farmacêutica, uso da formulação farmacêutica, frasco e kit
BR112015004091A2 (pt) formulação de cápsula de compósito farmacêutico que compreende irbesartan e inibidor de hmg-coa redutase

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B15K Others concerning applications: alteration of classification

Ipc: A61K 9/16 (2006.01), A61K 47/30 (2006.01), A61K 31

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2473 DE 29-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.